Veraxa Biotech is trading 8.8% up at $2.19 in pre-market, extending a sharp rebound driven by broader biotech sector strength and improved risk appetite.
- The move follows a 16.1% gain on July 27, 2026, which was attributed to a sector-wide rally rather than company-specific news.
- No fresh announcements or filings have been released overnight to explain the continued upward momentum.